SCHEMBL23802016

SCHEMBL23802016

COc1c(Br)cc(C(C)(C)C)cc1C=O

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PRKDC P78527 1/20 0.44
CA2 P00918 2/20 0.37
CA4 P22748 1/20 0.37
ERN1 O75460 4/20 0.37
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
KDM4E B2RXH2 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
CA1 P00915 1/20 0.35
CYP1A2 P05177 2/20 0.35
CYP2C19 P33261 2/20 0.35
MCL1 Q07820 1/20 0.35
CYP2D6 P10635 1/20 0.35
CYP2C9 P11712 1/20 0.35
HIF1A Q16665 1/20 0.35
MAPT P10636 1/20 0.35
HPGD P15428 1/20 0.35
HSD17B10 Q99714 1/20 0.34
LMNA P02545 1/20 0.34
MEN1 O00255 2/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15674456 0.83 LMNA (0.36) PRKDCALDH1A1CYP1A2CYP2C19CYP2D6
SCHEMBL4874926 0.83 HSD17B10 (0.40) PRKDCCA2CA4ERN1ALDH1A1
SCHEMBL4877589 0.82 MAPT (0.39) PRKDCCA2CA4ERN1ALDH1A1
SCHEMBL1054399 0.81 CA2 (0.48) CA2CA4ALDH1A1TSHRTDP1
SCHEMBL314046 0.81 RARG (0.42) PRKDCCA2ERN1ALDH1A1TSHR
SCHEMBL12680587 0.80 ERN1 (0.35) PRKDCERN1ALDH1A1KDM4ECYP1A2
SCHEMBL16829498 0.79 ALDH1A1 (0.36) PRKDCCA2ERN1ALDH1A1TSHR
SCHEMBL16119936 0.79 PRKDC (0.34) PRKDCCA2ERN1ALDH1A1TSHR
SCHEMBL3478814 0.79 THRA (0.43) PRKDCALDH1A1CYP1A2CYP2C19CYP2D6
SCHEMBL1119262 0.78 PRKDC (0.50) PRKDCCA2CA4ERN1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210284638-A1 ALPHAvBETA1 INTEGRIN ANTAGONISTS SAINT LOUIS UNIVERSITY (US) 2021-09-16 US disclosed
US-20210284638-A1 ALPHAvBETA1 INTEGRIN ANTAGONISTS SAINT LOUIS UNIVERSITY (US) 2021-09-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20210284638-A1 ALPHAvBETA1 INTEGRIN ANTAGONISTS ITGB1, ITGAV, ITGA1 PRKDC 3179/4885CA2 1928/4885CA4 2249/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.